Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome

INTRODUCTION: Radium-223 (Ra223) prolongs the survival and improves the quality of life of men with metastatic, castration-resistant prostate cancer (mCRPC) to bones. However, compared to other mCRPC therapies, using Ra223 comes with its unique challenges. Hence, we aimed to identify Ra223 utilizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Sierra, Arciero, Vanessa, Goldberg, Hanan, Tajzler, Camilla, Manganaro, Aileen, Kozlowski, Natascha, Rowbottom, Leigha, McDonald, Rachel, Chow, Ronald, Vasisht, Gaurav, Shaji, Sharon, Wong, Emily Chu Lee, Petrovic, Michele, Zhang, Liying, Phillips, Cameron, Zalewski, Pawel, Kapoor, Anil, Fleshner, Neil E, Chow, Edward, Emmenegger, Urban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827438/
https://www.ncbi.nlm.nih.gov/pubmed/31802949
http://dx.doi.org/10.2147/CMAR.S213051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827438/
https://www.ncbi.nlm.nih.gov/pubmed/31802949
http://dx.doi.org/10.2147/CMAR.S213051

Ejemplares similares